Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study

Bandini, Marco; Pompe, Raisa S.; Marchioni, Michele; Zaffuto, Emanuele; Gandaglia, Giorgio; Fossati, Nicola; Cindolo, Luca; Montorsi, Francesco; Briganti, Alberto; Saad, Fred; Karakiewicz, Pierre I.

doi:10.1007/s11255-017-1744-2

Cited by 38 publications

(36 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study also shares limitations of all similar studies that were based on the SEER database and relied on a retrospective data design . Furthermore, despite the large sample size, the current study cohort only represents approximately 30% of the population sample with inherent limitations . Despite having the largest absolute and relative numbers of AAs compared with all previous studies that focused on racial disparities in LND rates, AAs do represent a minority relative to NHWs in the current study (14.5%) .…”

Section: Discussionmentioning

confidence: 82%

Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis

et al. 2018

Self Cite

View full text Add to dashboard Cite

Contemporary North American African American patients treated with radical prostatectomy have equal access to lymph node dissection, the same lymph node invasion rates and the same cancer-specific mortality rates as non-Hispanic whites. However, the extent of lymph node dissection is lower in African Americans. The results regarding lymph node dissection rates are encouraging. However, improvements are required regarding lymph node dissection extent in African Americans.

show abstract

Section: Discussionmentioning

confidence: 82%

Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…A previous study reported an increase in survival in men with metastatic prostate cancer in Denmark whereas in The Surveillance, Epidemiology and End Results (SEER) cohorts in the US no change in survival had occurred between 1980 and 2008 [24]. A more recent update of the SEER cohort showed a slightly increased survival in men with de novo metastatic prostate cancer [25]. These studies did not include data on PSA and Gleason grade so cancer extent and cancer differentiation could not be assessed, nor was there any indication on use of chemotherapy.…”

Section: Discussionmentioning

confidence: 95%

Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study

et al. 2019

View full text Add to dashboard Cite

Background: There have been large changes in the pattern of detection, work-up and treatment of men with prostate cancer during the last two decades. Therefore, we aimed to investigate temporal changes in survival in men with metastatic prostate cancer. Methods: Population-based cohort study in Prostate Cancer data Base Sweden of 13,709 men with de novo metastatic prostate cancer diagnosed between 1998 and 2015. Overall survival in four calendar periods were compared by the use of Kaplan-Meier analyses and Cox regression models including age at diagnosis, T stage and serum levels of prostate-specific antigen (PSA). Results: Between 1998-2001 and 2010-2015, median survival increased with 6 months for all men. The largest increase in survival was 14 months in men age 60-69 at diagnosis and in multivariable analysis risk of death decreased for men diagnosed in 2010-2015 compared to 1998-2001, hazard ratio (HR) 0.77 (95% CI: 0.68-0.86). The median PSA at date of diagnosis decreased with 46% from 181 ng/mL in 1998 to 98 ng/mL in 2015. Conclusions: There was an increase in survival among men with de novo metastatic prostate cancer in Sweden between 1998 and 2015. This increase was due to a decreased cancer extent indicated by lower PSA levels with ensuing longer lead times and speculatively also due to an increased use of chemotherapy in the latest time period. Given the increasing use of systemic treatment for advanced prostate cancer, our results are likely heralding larger increases in survival in men with metastatic prostate cancer in the near future.

show abstract

“…Isolated bone metastases can be resected surgically and radiation may be effective in controlling symptoms. If the patient is asymptomatic, then observation with repeated radiographs may suffice [6]. The usage of bisphosphonate or RANKL inhibitors should be considered to reduce skeletally related events or fractures.…”

Section: Clinical Presentation and Therapeutic Managementmentioning

confidence: 99%

A short-term retrospective analysis of the clinical, histopathological and immunohistochemical aspects of bone metastases

Cîrstoiu

Munteanu

Georgescu

et al. 2019

Romanian Journal of Orthopaedic Surgery and Traumatology

View full text Add to dashboard Cite

Bone is a typical location of metastasis that usually reflects a negative outcome in oncologic patients. Once cancer has spread to the bones, it can rarely be cured, but sometimes it can be treated to minimize its rate of proliferation. Most skeletal metastases are produced by tumors originating in the breast and prostate. Osseous metastases are actually much more frequent than primary bone tumors, especially in adults. The diagnosis relies on signs, symptoms, and imaging techniques. This paper is a review of all cases of bone metastasis from our unit and a comprehensive review regarding the clinical approach and treatment of patients with such lesions.

show abstract

Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study

Abstract: This population-based study provides the first evidence of improved CSM free survival and OM free survival in patients with de novo mPCa since the introduction of several systemic agents for CRPC patients.

Cited by 38 publications

References 19 publications

Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis

Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis

Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study

A short-term retrospective analysis of the clinical, histopathological and immunohistochemical aspects of bone metastases

Contact Info

Product

Resources

About